Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 15/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 15/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885224 | 0.80 | PDGFRB (0.56) | PDGFRBPDGFRAEGFRALDH1A1GAA | |
| SCHEMBL3395817 | 0.78 | PDGFRB (0.58) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL8118643 | 0.76 | PDGFRB (0.62) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL24614203 | 0.71 | PDGFRB (0.60) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL3908370 | 0.71 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRLCKPGK1 | |
| SCHEMBL24894766 | 0.70 | PDGFRB (0.59) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL29338738 | 0.69 | PDGFRB (0.71) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL3908347 | 0.67 | PDGFRB (0.75) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL12775532 | 0.66 | ALDH1A1 (0.50) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL3909786 | 0.66 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRLCKNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001946-B1 | QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1687642-B1 | Screening methods for combinations of biological compounds | CENTELION (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| EP-1687642-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005038465-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-6482834-B2 | ANTIPROLIFERATION AGENTS; ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-09-20 | — | — | US | disclosed |
| US-6245760-B1 | ANTICANCER AGENTS; ANTIINFLAMMATORYA GENTS; SKIN DISORDERS | AVENTIS PHARMACEUTICALS PRODUCTS, INC | 2001-06-12 | — | — | US | disclosed |
| EP-1001946-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1001946-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998054157-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | MCL1, ABL1, TIE1 | PDGFRB 13/4885PDGFRA 10/4885EGFR 116/4885 |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.